Regulus Therapeutics Inc (RGLS NASDAQ) stock market data APIs
$7.889
-0.05(-0.6%)
as of May 8, 2025
Regulus Therapeutics Inc Financial Data Overview
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Prev. Close
7.889
Open
7.8345
High
7.9319
Low
7.7708
52 wk Range
0.8301-8.2
Market Cap
543 M
Shares Outstanding
66 243 K
Revenue
5 000 K
Beta
1.023
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Regulus Therapeutics Inc data using free add-ons & libraries
Get Regulus Therapeutics Inc Fundamental Data
Regulus Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 000 K
- EBITDA: -49 693 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regulus Therapeutics Inc News
New
Novartis to buy Regulus Therapeutics for as much as $1.7 billion
Vasant Narasimhan is the chief executive of Swiss pharmaceutical company Novartis. (Ruben Sprich / AFP / Getty Images) Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that co...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Protect Your Portfolio Against Market Uncertainty Disco...
Novartis to acquire Regulus in deal for kidney disease drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novartis will pay $800 million upfront to acquire Reg...
Novartis to Acquire Regulus in $1.7 Billion Deal
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
